The validity and specificity of URGCP immunostaining was determined by performing IHC staining with anti-URGCP antibody, a recombinant URGCP peptide that specifically blocks the anti-URGCP antibody, and IgG antibody as a negative control, showing strong staining intensity for anti-URGCP antibody, in contrast to the lack of specific staining for the URGCP peptide and IgG antibody in human clinical NSCLC specimens (Fig. 1F). Here, URGCP is linked to non-small cell lung carcinoma.